The effect of vitamin D use on ankle-brachial index in diabetic patients

Phase 3

Recruiting

Conditions: Patients with type 2 diabetes.
Diabetes mellitus due to underlying condition

Registration Number: IRCT20190919044819N4

Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Patients with type 2 diabetes who had no vascular intervention in the 2 months prior to the study
Type 2 diabetic patients who are examined by an endocrinologist for vitamin D deficiency with a serum level of 25 hydroxyvitamin D less than 30 ng / ml
Have peripheral arterial disease with an ankle-arm index less than 0.9 or equal to / More than 1.3
Patients with type 2 diabetes willing to cooperate and signing the written consent.

Exclusion Criteria

Suffering from any acute illness
Diabetic patients with kidney or liver dysfunction
Use medications including vitamins, calcium, lipid-lowering drugs, estrogen
Previous diseases that cause major changes in vitamin D and calcium metabolism, such as hyperparathyroidism or hypoparathyroidism or nephrolithiasis, or other drugs that affect bone metabolism
Use any drug that alters vitamin D metabolism, such as rifampin, phenytoin, or phenobarbital.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ankle-brachial index score. Timepoint: After 12 weeks of supplementation. Method of measurement: Vascular Doppler device.;Vitamin 25 hydroxy D levels. Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.;Total cholesterol (TC). Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.;Serum calcium. Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.;Triglyceride (TG). Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.;Low-density lipoprotein (LDL). Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.;High-density lipoprotein (HDL). Timepoint: After 12 weeks of supplementation. Method of measurement: Blood tests.

Secondary Outcome Measures